I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional
(outside the UK) and Australia:

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

APVRS 2022

-
Coming soon
03:54 AM
Duration 7mins Meeting Room 701E
Efficacy, Durability and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Lai T, Haskova Z, Mohan S, Silverman D, Tang Y, Lin H

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
06:27 AM
Duration 7mins Meeting Room 701E
Design and Rationale of the SALWEEN Trial: A Phase 3b/4 Study of Faricimab, a Dual Angiopoietin-2 and Vascular Endothelial Growth Factor-A Inhibitor, in Patients With Polypoidal Choroidal Vasculopathy
Lee WK, Lai T, Iida T, Chen S, Margaron P, Cheung G

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
06:34 AM
Duration 7mins Meeting Room 701E
End-of-Study Retinal Fluid and Vision Outcomes in the 96-week Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Lai T, Rachitskaya A, Blotner S, Heinrich D, Gune S

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
06:41 AM
Duration 7mins Meeting Room 701E
Portal Extension Trial of the Port Delivery System With Ranibizumab (PDS): Three-Year Follow-Up From the Phase 3 Archway Trial
Chen S, Regillo C, Cavichini Cordeiro M, Blotner S, Jaycock P, Gune S

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
07:09 AM
Duration 7mins Meeting Room 701E
Central Subfield Thickness Fluctuations and Their Impact on Vision Outcomes Over 96 Weeks in the Archway Trial of the Port Delivery System With Ranibizumab (PDS)
Hwang Y, Chakravarthy U , Blotner S, Heinrich D, Gune S, Sheth V

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:15 PM
Duration 5mins Taipei, Taiwan
View the APVRS symposium on "Expert clinical insights: Continous delivery of anti-VEGF for the managament of nAMD"
Hwang Y-S, Koh A, Lai T, and Fung A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
05:52 AM
Duration 7mins Meeting Room 701E
Faricimab in Neovascular Age-Related Macular Degeneration: Year 1 Results With Week 12 Fluid Data From the Phase 3 TENAYA and LUCERNE Trials
Guymer R, Cheung G, Souverain A, Yang M, Kotecha A, Margaron P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
05:59 AM
Duration 7mins Meeting Room 701E
Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE/RHINE Trials of Faricimab in Diabetic Macular Edema
Chen S, Jaffe GJ, Gerendas BS, Camino A, Tang Y, Haskova Z

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
06:06 AM
Duration 7mins Meeting Room 701E
Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Cheung G, Holz F, Khanani AM, Kotecha A, Patel V, Willis J

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
06:13 AM
Duration 7mins Meeting Room 701E
Intraocular Suppression of VEGF-A and Ang-2 Following Intravitreal Administration of Faricimab
Diack C*, Avery R, Stoilov I, Bogman K

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 7mins Meeting Room 701E
Angiopoietin-2 Signalling and Vascular Stability With Faricimab in Diabetic Macular Edema
Liu PK, Haskova Z, Joussen A, Willis JR, Westenskow PD

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
06:20 AM
Duration 7mins Meeting Room 701E
Faricimab in Neovascular Age-Related Macular Degeneration (nAMD): Year 2 Patient Case Profiles From the Phase 3 TENAYA/LUCERNE Trials
Koh A, Figueroa M, Pearce I, Swaminathan B, Patel V, Kotecha A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
06:27 AM
Duration 7mins Meeting Room 701E
Supplemental Intravitreal Ranibizumab Injections in Patients with the Port Delivery System With Ranibizumab (PDS) in the Phase 3 Archway Trial for Neovascular Age-Related Macular Degeneration (nAMD)
Chang A, Pieramici D, Gune S, DeGraaf S, Barteselli G, Heinrich D

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 7mins Meeting Room 701G
Key Surgical Pearls for Best Practice During the Port Delivery System With Ranibizumab (PDS) Implant Insertion Procedure
Okada M, Wieland M, Jaycock P, Menezes A, Singh N, Malhotra V

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:15 PM
Duration 5mins Taipei, Taiwan
View the APVRS symposium on "Advancing the management of nAMD and DME via Ang-2/VEGF-A dual inhibition"
Chen S-J, Cheung G, Chang A, and Singer M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar